Going Generic: Big Brands Poised To Lose Marketing Exclusivity In The US In 2019
Executive Summary
With the first generic versions of blockbuster brands like Advair, Lyrica, Restasis and Sensipar and the first biosimilars of Herceptin, Avastin and Rituxan expected to launch in the US, 2019 could be a notable year for generics and biosimilars.
You may also be interested in...
Biogen Vumerity Receives Full US Approval, But GI Comparison With Tecfidera Must Wait
Label offers little differentiation from Tecfidera, but head-to-head trial with custom-designed patient-reported outcome could make case for gastrointestinal tolerability advantage.
R&D Head Ehlers Bows Out As Confidence In Biogen's Pipeline Suffers From Setbacks
EVP Michael Ehlers swaps public company scrutiny for early-stage, venture-funded opportunities at Apple Tree Partners and Limelight Bio, while CMO and longtime Biogen executive Alfred Sandrock reclaims R&D oversight role.
IPF Failure Sets Back Biogen’s Diversification Efforts
The company has discontinued a Phase II trial for BG00011, which was acquired in its 2012 Stromedix purchase, due to safety issues.